MX2021008590A - Metodos para caracterizar enlaces de disulfuro. - Google Patents

Metodos para caracterizar enlaces de disulfuro.

Info

Publication number
MX2021008590A
MX2021008590A MX2021008590A MX2021008590A MX2021008590A MX 2021008590 A MX2021008590 A MX 2021008590A MX 2021008590 A MX2021008590 A MX 2021008590A MX 2021008590 A MX2021008590 A MX 2021008590A MX 2021008590 A MX2021008590 A MX 2021008590A
Authority
MX
Mexico
Prior art keywords
peptides
disulfide bond
drug product
protein drug
disulfide bonds
Prior art date
Application number
MX2021008590A
Other languages
English (en)
Inventor
Shunhai Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021008590A publication Critical patent/MX2021008590A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry

Abstract

Se proporcionan composiciones y métodos para analizar enlaces de disulfuro. Un método de ejemplo incluye preparar estándares de péptidos que no tienen enlaces de disulfuro, estándares de péptidos de enlaces de disulfuro desalineados, y estándares de péptidos de enlaces de disulfuro nativos de acuerdo con la secuencia de la región del producto farmacológico de proteína que incluye el enlace de disulfuro, digerir una muestra de productos farmacológicos de proteína en péptidos, separar los péptidos de producto farmacológico de proteína, analizar los péptidos de producto farmacológico de proteína y los estándares de péptidos, identificar péptidos de enlaces de disulfuro nativos y desalineados por el tiempo de retención y cuantificar el nivel de péptidos de enlaces de disulfuro desalineados.
MX2021008590A 2019-01-16 2020-01-16 Metodos para caracterizar enlaces de disulfuro. MX2021008590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962792994P 2019-01-16 2019-01-16
PCT/US2020/013907 WO2020150491A1 (en) 2019-01-16 2020-01-16 Methods for characterizing disulfide bonds

Publications (1)

Publication Number Publication Date
MX2021008590A true MX2021008590A (es) 2021-08-11

Family

ID=69570836

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021008589A MX2021008589A (es) 2019-01-16 2020-01-16 Metodos para identificar tioles libres en proteinas.
MX2021008590A MX2021008590A (es) 2019-01-16 2020-01-16 Metodos para caracterizar enlaces de disulfuro.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021008589A MX2021008589A (es) 2019-01-16 2020-01-16 Metodos para identificar tioles libres en proteinas.

Country Status (19)

Country Link
US (4) US11674968B2 (es)
EP (3) EP3857236A1 (es)
JP (2) JP2022517720A (es)
KR (2) KR20210114927A (es)
CN (3) CN117110492A (es)
AU (2) AU2020208396A1 (es)
BR (2) BR112021009544A2 (es)
CA (2) CA3116732A1 (es)
DK (1) DK3857237T3 (es)
EA (2) EA202191699A1 (es)
ES (1) ES2942024T3 (es)
FI (1) FI3857237T3 (es)
HU (1) HUE061783T2 (es)
IL (2) IL284473A (es)
MX (2) MX2021008589A (es)
PL (1) PL3857237T3 (es)
SG (2) SG11202104103XA (es)
WO (2) WO2020150492A1 (es)
ZA (2) ZA202102547B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303371A (en) * 2020-12-20 2023-08-01 Regeneron Pharma Methods for the identification of degraded disulfides in biocompounds
US20240060988A1 (en) * 2021-02-25 2024-02-22 Dr. Reddy’S Laboratories Limited Thiol variants and analytical methods thereof
CN113189254B (zh) * 2021-05-08 2021-11-16 北京工商大学 一种基于白酒中挥发性硫醇化合物的测定方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
KR101839163B1 (ko) * 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US20130259806A1 (en) * 2010-12-09 2013-10-03 David Light Dimeric molecular complexes with free cysteine residues and conjugates thereof
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
HUE038570T2 (hu) 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
BR112014017882A2 (pt) 2012-01-23 2017-06-27 Regeneron Pharma formulações estabilizadas contendo anticorpos anti-ang-2
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US9835629B2 (en) 2012-05-18 2017-12-05 Pierce Biotechnology, Inc. Methods and reagents for biomolecule labeling, enrichment and gentle elution
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CA2881679C (en) 2012-08-13 2021-01-26 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
US10690676B2 (en) 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
AU2015317899A1 (en) 2014-09-16 2017-04-06 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CN108627647B (zh) * 2017-03-24 2020-06-19 四川大学 一种翻译后修饰蛋白质组学的检测和定量方法
CN109142561A (zh) * 2018-07-17 2019-01-04 上海师范大学 同时定量蛋白质丰度与半胱氨酸氧化水平的方法及其应用

Also Published As

Publication number Publication date
CN117110492A (zh) 2023-11-24
CN113272651A (zh) 2021-08-17
EP4220173A3 (en) 2023-10-18
US11674968B2 (en) 2023-06-13
WO2020150492A1 (en) 2020-07-23
US20200225245A1 (en) 2020-07-16
BR112021009543A2 (pt) 2021-08-17
SG11202104237YA (en) 2021-05-28
JP2022517721A (ja) 2022-03-10
IL284471A (en) 2021-08-31
ZA202102546B (en) 2023-10-25
FI3857237T3 (fi) 2023-05-03
BR112021009544A2 (pt) 2021-10-26
KR20210114927A (ko) 2021-09-24
SG11202104103XA (en) 2021-05-28
MX2021008589A (es) 2021-08-11
JP2022517720A (ja) 2022-03-10
WO2020150491A1 (en) 2020-07-23
EP3857236A1 (en) 2021-08-04
KR20210114926A (ko) 2021-09-24
CA3116732A1 (en) 2020-07-23
CN113272651B (zh) 2023-06-16
EP4220173A2 (en) 2023-08-02
US20230280354A1 (en) 2023-09-07
EP3857237B1 (en) 2023-03-01
US20200225243A1 (en) 2020-07-16
EA202191841A1 (ru) 2021-10-07
ES2942024T3 (es) 2023-05-29
IL284473A (en) 2021-08-31
PL3857237T3 (pl) 2023-07-10
CN113272650A (zh) 2021-08-17
DK3857237T3 (da) 2023-05-01
EP3857237A1 (en) 2021-08-04
EA202191699A1 (ru) 2021-10-11
US20230273216A1 (en) 2023-08-31
HUE061783T2 (hu) 2023-08-28
ZA202102547B (en) 2023-10-25
AU2020208396A1 (en) 2021-05-20
US11579150B2 (en) 2023-02-14
CA3116735A1 (en) 2020-07-23
AU2020208395A1 (en) 2021-05-20
WO2020150492A8 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
ZA202102547B (en) Methods for characterizing disulfide bonds
WO2020102741A8 (en) Methods and compositions for protein sequencing
EP4299803A3 (en) Macromolecule analysis employing nucleic acid encoding
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MX2018009339A (es) Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
BR112018071107A2 (pt) composições e métodos para a detecção de proteínas da célula hospedeira
MX2018010470A (es) Proteinas de fusion folistatina-fc recombinantes y su uso en el tratamiento de la distrofia muscular de duchenne.
EA202192850A1 (ru) Идентификация белков клетки-хозяина
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
WO2021236716A3 (en) Methods, systems and kits for polypeptide processing and analysis
WO2022256840A3 (en) Methods for screening particle formulations comprising proteins
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
MX2021007518A (es) Metodo de extraccion de proteina a partir de material vegetal de cannabis.
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
WO2021009669A3 (en) A process for separation and quantitation of proteins using capillary electrophoresis
MX2018003445A (es) Expresion de proteinas que contienen fc.
ZA202003249B (en) A dual-column lc-ms system and methods of use thereof
MX2020001818A (es) Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra.
CR20220065A (es) Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc
AU2021270786A8 (en) Sample preparation for mass spectrometry
MX2022007838A (es) Aislado de proteina de chicharo con bajo contenido en lipidos.